TARDBP and amyotrophic lateral sclerosis: Concerning mAb delivery, it was recently tested in vivo in transgenic mouse models of ALS/FFTD, showing mitigating effects such as cognitive impairment, motor defects, TDP-43 proteinopathy, and neuroinflammation [193].